EA201000383A1 - Способ ингибирования клостридиум диффициле введением оритаванцина - Google Patents

Способ ингибирования клостридиум диффициле введением оритаванцина

Info

Publication number
EA201000383A1
EA201000383A1 EA201000383A EA201000383A EA201000383A1 EA 201000383 A1 EA201000383 A1 EA 201000383A1 EA 201000383 A EA201000383 A EA 201000383A EA 201000383 A EA201000383 A EA 201000383A EA 201000383 A1 EA201000383 A1 EA 201000383A1
Authority
EA
Eurasian Patent Office
Prior art keywords
clostridium difficile
oritawan
introduction
inhibiting clostridium
preventing
Prior art date
Application number
EA201000383A
Other languages
English (en)
Other versions
EA017564B1 (ru
Inventor
Марк Харви Уилкокс
Саймон Бейнс
Дарио Леу
Томас Р. Парр
Original Assignee
Тарганта Терапьютикс Корп.
Юнивёсити Оф Лидз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тарганта Терапьютикс Корп., Юнивёсити Оф Лидз filed Critical Тарганта Терапьютикс Корп.
Publication of EA201000383A1 publication Critical patent/EA201000383A1/ru
Publication of EA017564B1 publication Critical patent/EA017564B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Гликопептидные антибиотики, такие как оритаванцин, проявляют значительную активность и против вегетативной формы клостридиум диффициле, и против спор клостридиум диффициле. В изобретении описаны способы лечения, профилактики и предотвращения инфекций и заболеваний, вызванных клостридиум диффициле, у животных, включая людей.
EA201000383A 2007-09-12 2008-09-11 Способ ингибирования клостридиум диффициле введением оритаванцина EA017564B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97176607P 2007-09-12 2007-09-12
PCT/US2008/075949 WO2009036121A1 (en) 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin

Publications (2)

Publication Number Publication Date
EA201000383A1 true EA201000383A1 (ru) 2010-10-29
EA017564B1 EA017564B1 (ru) 2013-01-30

Family

ID=40452464

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000383A EA017564B1 (ru) 2007-09-12 2008-09-11 Способ ингибирования клостридиум диффициле введением оритаванцина

Country Status (10)

Country Link
US (3) US8518873B2 (ru)
EP (1) EP2195004B1 (ru)
JP (1) JP5591112B2 (ru)
CN (1) CN102316885A (ru)
AU (1) AU2008298987B2 (ru)
BR (1) BRPI0816662A2 (ru)
CA (1) CA2699550C (ru)
EA (1) EA017564B1 (ru)
ES (1) ES2535928T3 (ru)
WO (1) WO2009036121A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008298987B2 (en) * 2007-09-12 2013-12-05 Melinta Therapeutics, Inc. Method of inhibiting clostridium difficile by administration of oritavancin
WO2009126502A2 (en) * 2008-04-08 2009-10-15 Targanta Therapeutics Corp. Methods of inhibiting and treating biofilms using glycopeptide antibiotics
EP2424559B1 (en) * 2009-04-28 2024-04-03 Melinta Therapeutics, LLC Methods of treating bacterial infections using oritavancin
JP5986416B2 (ja) * 2012-04-11 2016-09-06 花王株式会社 皮膚外用剤
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
BR112015018625A2 (pt) 2013-02-04 2017-09-19 Seres Therapeutics Inc composições e métodos
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
BR112016011830A2 (pt) 2013-11-25 2017-09-26 Seres Therapeutics Inc composições bacterianas sinergísticas e métodos para produção e uso das mesmas.
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10191380B2 (en) * 2014-10-14 2019-01-29 Az Electronic Materials (Luxembourg) S.A.R.L. Composition for resist patterning and method for forming pattern using same
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
BR112018016715A2 (pt) 2016-02-18 2019-02-19 Melinta Therapeutics, Inc. ?formulações de oritavancina?
CN107325159A (zh) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
EA201892413A1 (ru) 2016-05-09 2019-05-31 Кселлия Фармасьютикалз Апс Стабилизированные препараты гликопептидного антибиотика
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
CA3109900A1 (en) * 2018-08-17 2020-02-20 Universidad Andres Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile
KR102444119B1 (ko) * 2020-04-22 2022-09-16 주식회사 인트론바이오테크놀로지 클로스트리디오이데스 디피실리 균에 대하여 용균 활성을 갖는 항균단백질 cdl200

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961184B2 (ja) * 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
US7317001B2 (en) * 2002-06-06 2008-01-08 Oscient Pharmaceuticals Corporation Use of ramoplanin to treat diseases associated with the use of antibiotics
DE60330161D1 (de) * 2002-08-29 2009-12-31 Activbiotics Pharma Llc Rifalazil zur behandlung von infektionen mit clostridium difficile
CN1918172B (zh) * 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
WO2007092582A2 (en) * 2006-02-08 2007-08-16 Biosynexus Incorporated Neutralization of bacterial spores
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
AU2008298987B2 (en) * 2007-09-12 2013-12-05 Melinta Therapeutics, Inc. Method of inhibiting clostridium difficile by administration of oritavancin

Also Published As

Publication number Publication date
JP2010539179A (ja) 2010-12-16
EA017564B1 (ru) 2013-01-30
BRPI0816662A2 (pt) 2017-06-13
US9220749B2 (en) 2015-12-29
WO2009036121A1 (en) 2009-03-19
CA2699550C (en) 2020-08-18
US20140100157A1 (en) 2014-04-10
ES2535928T3 (es) 2015-05-19
EP2195004A4 (en) 2011-12-28
US8629100B2 (en) 2014-01-14
CN102316885A (zh) 2012-01-11
AU2008298987B2 (en) 2013-12-05
US20130310308A1 (en) 2013-11-21
EP2195004B1 (en) 2015-04-01
JP5591112B2 (ja) 2014-09-17
CA2699550A1 (en) 2009-03-19
AU2008298987A1 (en) 2009-03-19
US8518873B2 (en) 2013-08-27
US20100311646A1 (en) 2010-12-09
EP2195004A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
PH12016502092A1 (en) Antimicrobial compounds and methods of making and using the same
MY176900A (en) Antimicrobial compounds and methods of making and using the same
MY173518A (en) Antimicrobial compounds and methods of making and using the same
SG170813A1 (en) New compounds
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MY177564A (en) Anti-nr10 antibody and use thereof
MX2009004047A (es) Compuestos organicos.
EA201101477A1 (ru) Органические соединения и их применение
PH12015502375A1 (en) Antimicrobial compounds and methods of making and using the same
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
TNSN08400A1 (en) Organic compounds and their uses
WO2007109105A3 (en) Flavivirus inhibition by sultams and related compounds
EA201100413A1 (ru) Способ лечения бактериальной инфекции
MY165011A (en) Antimicrobial compounds and methods of making and using the same
TW200716132A (en) Novel chemical compounds
MY154715A (en) Anti-nr10 antibody and use thereof
WO2005071067A3 (en) Non-animal origin stabilizers and processes for producing the same
WO2008097364A3 (en) Use of oritavancin for prevention and treatment of anthrax
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
MX2021013281A (es) Uso de molindona para el tratamiento de agresion.
TW200716579A (en) Novel chemical compounds
WO2008033477A3 (en) Antimicrobial activity in variants of lacritin
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
WO2011103458A3 (en) Compositions and methods for using and identifying antimicrobial agents

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment